Background Patients often receive advanced imaging before referral to an orthopaedic oncologist. The few studies that have evaluated the value of these tests have been single-center studies, and there were large discrepancies in the estimated frequencies of unnecessary use of diagnostic tests. Questions/purposes (1) Is there regional variation in the use of advanced imaging before referral to an orthopaedic oncologist? (2) Are these prereferral studies helpful to the treating orthopaedic oncologist in making a diagnosis or treatment plan? (3) Are orthopaedic surgeons less likely to order unhelpful studies than other specialties? (4) Are there any tumor or patient characteristics that are associated with the ordering of an unhelpful study? Methods We performed an eight-center prospective analysis of patients referred for evaluation by a fellowshiptrained orthopaedic oncologist. We recorded patient factors, referral details, advanced imaging performed, and presumptive diagnosis. The treating orthopaedic oncologist determined whether each study was helpful in the diagnosis or treatment of the patient based on objective and subjective criteria used in prior investigations. We analyzed the data using bivariate methods and logistic regression to determine regional variation and risk factors predictive of unhelpful advanced imaging. Of the 371 participants available for analysis, 301 (81%) were referred with an MRI, CT scan, bone scan, ultrasound, or positron emission tomography scan. Results There were no regional differences in the use of advanced imaging (range of patients presenting with advanced imaging 66%-88% across centers, p = 0.164).
One hundred thirteen patients (30%) had at least one unhelpful study; non-MRI advanced imaging was more likely to be unhelpful than MRIs (88 of 129 [68%] non-MRI imaging versus 46 of 263 [17%] MRIs [p \ 0.001]). Orthopaedic surgeons were no less likely than nonorthopaedic surgeons to order unhelpful studies before referral to an orthopaedic oncologist (56 of 179 [31%] of patients referred by orthopaedic surgeons versus 35 of 119 [29%] referred by primary care providers and 22 of 73 [30%] referred by nonorthopaedic specialists, p = 0.940). After controlling for potential confounding variables, benign bone lesions had an increased odds of referral with an unhelpful study (59 of 145 [41%] of benign bone tumors versus 54 of 226 [24%] of soft tissue tumors and malignant bone tumors; odds ratio, 2.80; 95% confidence interval, 1.68-4.69, p \ 0.001).
Conclusions We found no evidence that the proportion of patients referred with advanced imaging varied dramatically by region. Studies other than MRI were likely to be considered unhelpful and should not be routinely ordered by referring physicians. Diligent education of orthopaedic surgeons and primary care physicians in the judicious use of advanced imaging in benign bone tumors may help mitigate unnecessary imaging. Level of Evidence Level III, diagnostic study. See Guidelines for Authors for a complete description of levels of evidence.
Introduction
The evaluation of a bone or soft tissue tumor of unknown etiology is a challenge most orthopaedic surgeons and primary care physicians will encounter in their career. The orthopaedic oncology community has advocated for decades for all suspected sarcomas to be referred, before biopsy, to a center capable of all facets of sarcoma treatment [14] . In contrast, there is little guidance on what should be done for the patient before referral. Physicians have a number of advanced imaging modalities available for use, including MRI, CT scan, bone scan, ultrasound, and positron emission tomography (PET) scan. Each of these tests is useful for the correct indications and wasteful when not needed to aid in the diagnosis or treatment of a tumor. Excessive medical imaging has been targeted as a substantial contributor to overspending in the US healthcare system (although some modalities are more expensive than others), and the need for appropriate use reform has been previously voiced [2, 3, 5-9, 11-13, 17-19] .
Previous single-center investigations have attempted to define the scope of advanced imaging use by nonorthopaedic oncologists with conflicting results. Aboulafia et al. [1] , in a prospective series of 100 patients, found that 34% of MRIs, 42% of bone scans, and 36% of CT scans were excessive and not needed for appropriate clinical management. In contrast, Martin et al. analyzed a retrospective series of 920 patients and determined that only 3% of patients had an excessive MRI [16] . This disagreement caused us to question whether the apparently discrepant use of advanced imaging and unnecessary studies are the result of regional differences or referral patterns. To our knowledge, no collaborative investigation across multiple institutions has been attempted.
Our questions were: (1) Is there regional variation in the use of advanced imaging before referral to an orthopaedic oncologist? (2) Are these prereferral studies helpful to the treating orthopaedic oncologist in making a diagnosis or treatment plan? (3) Are orthopaedic surgeons less likely to order unhelpful studies than other specialties? (4) Are there any tumor or patient characteristics that are associated with the ordering of an unhelpful study?
Patients and Methods
Eight fellowship-trained orthopaedic oncologists at separate institutions across the United States agreed to participate in this investigation. Because our goal was to reflect an accurate view of our individual practices, each investigator personally evaluated 50 patients or 6 months (whichever occurred first) of consecutive new patient referrals for diagnosis or treatment of a possible bone or soft tissue tumor. This resulted in a possible sample of 371 patients' records; of those, 371 (100%) were available for analysis. We included all age groups, both bone and soft tissue tumors, and all anatomic locations. The data were then deidentified and combined for analysis. We obtained approval from the institutional review board of all participating centers before patient enrollment.
We recorded patient details (age, sex, race, insurance status), tumor type (bone or soft tissue), specialty of the referring physician, distance traveled by the patient, presumptive diagnosis, and the imaging studies performed before referral (MRI, CT scan, bone scan, ultrasound, PET scan). We only recorded CT scans performed to evaluate the tumor itself and not those scans performed for staging. We did not distinguish among PET alone, PET/CT, or PET/MRI and all were included under ''PET scan.'' The presumptive diagnosis was determined by each individual orthopaedic oncologist based on the patient's history, physical examination, and imaging characteristics. The clinical impression was recorded as likely benign, likely malignant, likely nonneoplastic, and unknown. For purposes of the statistical analysis, lesions that were labeled as ''likely malignant'' or ''unknown'' were classified as malignant, whereas lesions that were called ''likely benign'' or ''likely nonneoplastic'' were classified as benign.
Among the 371 patients from the eight centers, there were 183 males and 188 females with a mean age of 45.2 years (range, 3-92 years). Two hundred nine lesions involved bone, of which 145 (69%) were thought to be benign. Of the 162 soft tissue tumors, 115 (71%) were labeled benign. A total of 301 patients (81%) had at least one advanced imaging study, and 81 (22%) had multiple studies. In order of decreasing frequency, there were 263 patients referred with an MRI (71%), 54 with a CT scan (15%), 40 with a bone scan (11%), 21 with an ultrasound (6%), and 14 with a PET scan (4%).
Each orthopaedic oncologist determined whether a study was helpful in all patients they personally evaluated. The criteria we used to determine a helpful study were extrapolated from previous investigations [1, 16] . Generally, advanced imaging was considered helpful if the study was one that the treating cancer specialists would routinely perform for a given condition (for instance, a bone scan for metastatic disease) or if the study aided in determining the diagnosis or formulating a treatment plan [1] . For MRIs specifically, we considered the study helpful for a soft tissue mass if it was (1) a biopsy-proven soft tissue sarcoma; (2) greater than 5 cm in diameter; (3) deep to the muscle fascia; (4) painful; or (5) growing [16] . In bone tumors, MRIs were always considered helpful if there was a suspicion for a primary malignancy of bone on a plain radiograph [16] .
Statistical Analysis
We performed a post hoc power analysis with a sample size of 50 patients per group. We performed a post hoc analysis because we did not have a reliable estimate of the use of prereferral advanced imaging. The sample size was more a matter of convenience, because this was the maximal number of patients and duration of study that all participants and study sites were able to provide with the resources available; we also sought to make this study substantially larger than the earlier prospective study on the same topic [1] . Assuming a prevalence rate of 79% of patients presenting with some form of advanced imaging, we found that we had 90% power to detect a 20% difference between various centers in the proportion of patients referred with advanced imaging, setting the alpha (p value) at \ 0.05.
Initially we conducted a bivariate analysis using t-tests for continuous variables and chi-square testing for categorical variables to determine associations between predictor variables (sex, age, race, practice location, insurance, referral source, presumptive diagnosis, and distance traveled) and the likelihood of an unhelpful study. We transformed age and distance traveled into categorical variables by dividing into quartiles.
Next, we performed univariate regression modeling to calculate odds ratios for unhelpful studies for each predictor variable. These variables were then combined into a multivariate logistic regression analysis controlling for all factors simultaneously. We chose the exploratory variables (sex, age, race, practice location, insurance, referral source, distance traveled, and presumptive diagnosis) because we considered these measurable factors that theoretically could influence the decision to perform prereferral advanced imaging. The statistical calculations were performed with SAS1 Version 9.3 (SAS Institute, Cary, NC, USA).
Interobserver Reliability
We performed interobserver reliability testing on a representative cohort of patients to determine a general estimate of potential agreement between the multiple participants. We collected all 31 of the patients at one of the author's (BJM) institutions who presented with an MRI. Each patient's case was prepared by the treating surgeon (BJM) with a brief history slide, including reports of pain, history of a growing mass, prior interventions, and any unique features of the presentation that may have been relevant in the decision to obtain an MRI. This was followed by images of the radiographs (when available) and representative slices of the MRI. Each participant then decided whether the MRI was helpful or unhelpful given our defined criteria. We then determined the interobserver agreement among the eight participants, yielding a kappa of 0.64, which is considered ''substantial agreement'' [20] .
Results
We found no differences in the use of advanced imaging when comparing across the eight study sites involved. We found substantial variation in the distribution of patient age, race, insurance status, and distance traveled over all the practice locations (Table 1) . Despite these differences, the use of advanced imaging was fairly similar across study sites, ranging from 66% (33 of 50) to 88% (44 of 50) of patients with some form of advanced imaging and 62% (31 of 50) to 80% (40 of 50) presenting with an MRI (Table 2) ; with the numbers available, these numbers were not different (p = 0.164 and p = 0.713, respectively).
One hundred thirteen patients (30%) were referred with at least one unhelpful study. The proportion of unhelpful MRIs (46 of 263 [17%]) was less than the proportion of unhelpful tests using other modalities (88 of 129 [68%]; p \ 0.001). Specifically, 40 of 54 (74%) CT scans, 25 of 40 (62%) bone scans, 16 of 21 (76%) ultrasounds, and seven of 14 (50%) PET scans were thought to be unhelpful. We found that 17 (6%) of the MRIs performed needed to be repeated as a result of lack of contrast (11) or inadequate visualization of the tumor, in which the study did not show the entire tumor extent (six). Musculoskeletal radiologists were variably involved in the decision to repeat an MRI.
Orthopaedic surgeons and nonorthopaedic surgeons were equally as likely to perform unhelpful advanced imaging (56 of 179 [31%] of patients referred by orthopaedic surgeons versus 35 of 119 [29%] referred by primary care providers and 22 of 73 [30%] referred by nonorthopaedic specialists, p = 0.940).
After controlling for the potential confounding variables of sex, age, race, insurance, referral source, tumor type, distance traveled, and practice location, the only factor we found that was associated with increased odds of an unhelpful study was the use of imaging in the diagnosis of a benign bone tumor (odds ratio, 2.80; 95% confidence interval, 1.68-4.69; p \ 0.001; Table 3 ).
Discussion
Most orthopaedic surgeons and primary care physicians will encounter a bone or soft tissue tumor of unknown etiology at some point in their career. Although many tumors will require advanced medical imaging to determine a diagnosis and formulate a treatment plan, some may be managed appropriately with only simple radiographs and longitudinal surveillance. We sought to determine if there were regional differences in the use of advanced imaging before referral to a sarcoma center and if that imaging tended to be helpful to the treating orthopaedic oncologist. A number of our findings are interesting and warrant further discussion. This investigation does have several limitations that deserve mention. Most apparent is that each case was reviewed by only the treating orthopaedic oncologist. This introduces an important source of potential bias because there may have been studies coded as helpful or unhelpful that would not be universally agreed on. Our limited kappa analysis estimated that the interobserver agreement was 0.64 (substantial agreement) and provides some justification of this study design. Similarly, we did not require a histologic diagnosis or prolonged period of monitoring to confirm a benign or malignant entity. However, the purpose of this study was to report on the actual clinical practice of orthopaedic oncology. Choices regarding the use of imaging modalities are routinely made by a single orthopaedic oncologist, typically without the benefit of a histologic diagnosis or documented long-term stability. In addition, the decision to perform advanced imaging may be based on a concerning history or abnormal examination finding, which would not be readily amenable to blinded multireviewer assessment.
Our intention was not to rigidly state when an imaging modality should be used. The conclusions simply suggest scenarios where the referring provider may defer the decision to the treating specialist. There is almost certainly interobserver variation in determining the appropriateness of advanced imaging in many clinical scenarios. Although that was not the focus of this investigation, it is an area in need of further study. It is also possible that advanced imaging studies were being ordered by referring physicians to avoid a delay in diagnosis or treatment. We should also note that we did not study the repercussions of a delay in testing or diagnosis. It is outside the scope of our investigation but clearly an important area for more investigation. An additional weakness is that our investigation was limited to the United States and our findings may not be applicable to other countries. Finally, this is a limited sampling of the tumor practice of several individuals. We did not find extreme differences in regional use of advanced imaging across the entire subset, but it is likely that subtle discrepancies remain. However, in the event that we are underpowered to analyze regional differences, it is not clear whether these differences would be clinically meaningful.
Questions may also arise regarding the finding of excessive imaging in benign bone tumors. Although many benign bone tumors can be accurately identified on plain radiographs, there are certainly many scenarios where it is appropriate to use additional imaging studies. Benign bone tumors are often found incidentally on an advanced imaging study without being apparent on plain radiographs. Incidental findings were not considered unhelpful for this investigation, because unintended identification of benign bone tumors is to be expected occasionally in the course of normal clinical practice. Furthermore, in this study, we only captured tumors referred to an orthopaedic oncologist, so our data do not include benign bone tumors that are not sent for specialist evaluation; it is conceivable that some insurers or practices require advanced imaging before referral is permitted to a subspecialist, and this could result in imaging tests being ordered on patients with benign tumors that might not otherwise have been ordered. Even with these exceptions, our report recognizes benign bone tumors as a substantial contributor to excessive advanced imaging and suggests that further work on this topic may be beneficial. We did find regional variation in patient demographics, suggesting that orthopaedic oncology referral bases differ by location in terms of patient age, race, insurance status, and distance from the treating center. However, we did not observe a regional difference in prereferral use of advanced imaging modalities. Because this is the first attempt to study this question across multiple institutions, the lack of extreme differences between demographically and geographically variable regions suggests that our findings and recommendations may be generalizable to orthopaedic oncology clinics outside of the institutions studied herein. This assertion requires further study, however, because our limited sampling of eight centers may not be robust enough to represent select regions in the United States and elsewhere.
We found the majority of the non-MRI advanced imaging modalities to be unhelpful, because most did not aid in the diagnosis or treatment of this cohort of patients. Our estimates were larger than those found by Aboulafia et al. [1] , who reported 42% of bone scans (compared with 62% in our series) and 36% of CT scans (compared with 74% in our series) were excessive. In contrast, MRIs were obtained in 71% of patients before referral and were found to be unhelpful in 17% of cases in which they were performed. This is within the range of previous reports of excessive MRIs, from 3% [16] to 34% [1] . We could not find any similar reports regarding the appropriate use of PET scan or ultrasound in this clinical scenario. These findings allow for two observations. First, CT scans, bone scans, ultrasounds, and PET scans were typically not helpful and may be best implemented at the discretion of the treating oncology specialists rather than the referring provider. Second, MRIs were found to be helpful in the majority of patients and generally were performed adequately. Therefore, referring physicians may consider performing an MRI before referral when a bone or soft tissue sarcoma is suspected. MRIs performed with intravenous contrast and visualizing the entire anatomic compartment in which the tumor resides minimize the need for repeating as a result of technical inadequacy.
Interestingly, we determined that orthopaedic surgeons and nonorthopaedic surgeons referred patients with a similar proportion of unhelpful imaging studies. This observation supports the findings of Aboulafia et al. [1] and calls to question the adequacy of educational efforts regarding appropriate use of advanced imaging in orthopaedic tumors. Although reports containing some mention of criteria for advanced imaging use in musculoskeletal tumors exist [4, 10, 15] , assessing the need for or necessity of a particular study remains quite subjective. Therefore, further defining objective, reproducible criteria for obtaining advanced imaging would be helpful to referring providers, postgraduate trainees, and orthopaedic oncologists. Furthermore, discussion of the clinical concern and appropriate method of imaging with a radiologist before completion of an advanced test may decrease excessive studies. These are important areas for further study and discussion.
Our most robust finding was the association between benign bone tumors and unhelpful advanced imaging. Specifically, benign bone tumors made up 39% of the cohort yet accounted for 33 of 46 (72%) of the unhelpful MRIs. This disparity supports the previous findings of Aboulafia et al. [1] . We have expanded on their report to demonstrate that this relationship remains significant in a multivariate model after controlling for practice location and patient-related factors. Many benign bone tumors have characteristic findings on plain radiographs, diminishing the need for cross-sectional imaging. The comfort of an orthopaedic oncologist or musculoskeletal radiologist to make the diagnosis of a benign bone tumor on radiographs alone likely distinguishes them from referring physicians and may account for the high number of unhelpful studies.
These data should not be used to advocate for elimination of all prereferral imaging, but rather to minimize the number of unnecessary studies performed and ensure the correct studies are done initially. It should not be overlooked that over half of the patients in our series did have advanced imaging that was considered helpful in their diagnosis and treatment. A previously performed study that is available for review at the time of an initial appointment can increase clinical efficiency by allowing for a more informative counseling session, a same-day biopsy, or avoiding a return appointment to obtain or discuss the study. Thus, the ideal scenario is not to reduce all excessive studies at the expense of appropriate and helpful prereferral imaging. Instead, we should focus on guiding use of advanced imaging when clinically indicated. To conclude, we found that the majority of patients sent to an orthopaedic oncology specialty clinic have some form of advanced imaging performed before referral. Although MRIs were generally useful, other forms of advanced imaging were likely to be wasteful. Efforts focusing on clearly defining the clinical indications for advanced imaging, emphasizing their overuse in benign bone tumors, may result in more appropriate use.
